Professor Wu Yilong is the domestic clinical specialist who firstly concerns to the lung cancer brain metastasis, and he started the clinical study for brain metastases in 2006, and performed the subgroup analysis particularly for brain metastases in AURA3 study. All those research achievements have been published in top-level learned periodical such as lancet, NEJM etc., and cause a hot discussion internationally. In the CSCO convention at the end of the September, 【Tumor information】conduct the exclusive interview to Professor Wu Yilong for the related issues of the treatment for EGFR mutation lung cancer brain metastasis as well as newest study development of the lung cancer brain metastasis drug AZD3759. Professor Wu Yilong deeply narrated the story behind the study of BLOOM and AZD3759.

Blockbuster! Professor Wu Yilong demystify the unbeknown side of BLOOM study

Alpha Biopharma is committed to the development of urgently needed innovative therapeutic drugs

Gather the classic personnel in the field of clinical development strategy/clinical trial implementation/market strategy/registration affairs and business expansion

Look for innovative drug targets that are already well established worldwide, and conduct the middle and later period clinical trial development (the project should be already in or complete the PoC stage)

The core development goal is to obtain the marketing authorization in China, and then drive the worldwide market

Strategic Positioning

View more>>

Latest Posts

 
→ More

Alpha Biopharma Announces Series A Financing

SHANGHAI, June 19, 2018 Alpha Biopharma Inc. ("AlphaBio") today announced the first $37M closing of its $65M Series A financing led by Qiming Venture Partners, one of the most prominent venture capital firms in China. Other notable investors that participated in the round included the TF Fund and the LYZZ Healthcare Venture Fund. The proceeds from this financing will be used to conduct a global multi-center Phase II clinical study of AZD3759, AlphaBio's lead product, as well as expansion of AlphaBio's product pipeline. Concurrent with the financing, Dr. William Hu, Managing Partner of Qiming Venture Partners, will join the Board of Directors of AlphaBio.

→ More

A Randomized, Open-label, Controlled, Multi-Center  Phase II/III  Study  to Assess the Efficacy and Safety of AZD3759  vs.  a Standard of Care EGFR TKI (Erlotinib or Gefitinib), as First Line Treatment in Patients with EGFR Mutation Positive Advanced NSCLC with CNS Metastasis

(Data Source: www.chinadrugtrials.org.cn)


Clinical TrialAZD3759 First-line treatment for advanced NSCLC with EGFR mutation positive accompanied by CNS metastasis







→ More

Good News! Alpha Biopharma, located in Taizhou Medical High-tech Zone, has becom the only potential unicorn enterprise in middle and north of Jiangsu Province

→ More

Professor Wu Yilong is the domestic clinical specialist who firstly concerns to the lung cancer brain metastasis, and he started the clinical study for brain metastases in 2006, and performed the subgroup analysis particularly for brain metastases in AURA3 study. All those research achievements have been published in top-level learned periodical such as lancet, NEJM etc., and cause a hot discussion internationally. In the CSCO convention at the end of the September, 【Tumor information】conduct the exclusive interview to Professor Wu Yilong for the related issues of the treatment for EGFR mutation lung cancer brain metastasis as well as newest study development of the lung cancer brain metastasis drug AZD3759. Professor Wu Yilong deeply narrated the story behind the study of BLOOM and AZD3759.

Blockbuster! Professor Wu Yilong demystify the unbeknown side of BLOOM study

Address unmet clinical needs

Gather the classic personnel in the field of clinical development strategy/clinical trial implementation/market strategy/registration affairs and business expansion

Look for innovative drug targets that are already well established worldwide, and conduct the middle and later period clinical trial development (the project should be already in or complete the PoC stage)

The core development goal is to obtain the marketing authorization in China, and then drive the worldwide market

Mission & Value
View more>>

Latest Posts

 
→ More